A5059596200- Platelet Disorders and Treatments
- Blood groups and transfusion
- Heparin-Induced Thrombocytopenia and Thrombosis
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Blood disorders and treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Hemophilia Treatment and Research
- Venous Thromboembolism Diagnosis and Management
- Complement system in diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Blood Coagulation and Thrombosis Mechanisms
- Chronic Myeloid Leukemia Treatments
- Blood properties and coagulation
- Blood transfusion and management
- Autoimmune Bullous Skin Diseases
- Renal Diseases and Glomerulopathies
- Chronic Lymphocytic Leukemia Research
- Hemostasis and retained surgical items
- Hemoglobinopathies and Related Disorders
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Pituitary Gland Disorders and Treatments
- Cystic Fibrosis Research Advances
- Eosinophilic Disorders and Syndromes
- Adrenal Hormones and Disorders
- Maternal and fetal healthcare
University of Milan
2014-2024
Luigi Sacco Hospital
2014-2024
Bambino Gesù Children's Hospital
2022-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2006-2022
Creative Electron (United States)
2018
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2003-2015
Marche Polytechnic University
2014
Ospedale Maggiore
1985-2010
Weatherford College
2009
Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers
2009
Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance aimed to collect data from adult who required hospitalisation for COVID-19.This multicentre, retrospective, cohort study included (aged ≥18 years) diagnosis of WHO-defined malignancy admitted 66 hospitals between Feb 25 May 18, 2020, laboratory-confirmed symptomatic COVID-19. Data cutoff analysis was June 22, 2020. primary...
Background Postpartum hemorrhage ( PPH ) remains one of the leading causes maternal morbidity and mortality worldwide, although lack a precise definition precludes accurate data absolute prevalence . Study Design Methods An international expert panel in obstetrics, gynecology, hematology, transfusion, anesthesiology undertook comprehensive review literature. At meeting N ovember 2011, agreed on severe that would identify those women who were at high risk adverse clinical outcomes. Results...
The acquired von Willebrand syndrome (AvWS) is a rare bleeding disorder with laboratory findings similar to those of congenital disease (vWD). Despite the numerous cases reported in literature until 1999 (n = 266), large studies on AvWS are not available. Moreover, diagnosis has been difficult and treatment empirical. These considerations prompted us organize an international registry. A questionnaire, devised collect specific information AvWS, was sent all members International Society...
Among all patients with von Willebrand disease (vWD), alloantibodies to factor (vWF) have been described only in severe vWD (type III). The relationship between the development of and nature genetic lesion is not known. In hemophilia B, large deletions within IX gene appear correlate occurrence alloantibodies, whereas A no such correlation apparent. We studied 19 recessive III) autosomal dominant I) by Southern blotting probes encompassing full 9 kilobases (kb) vWF cDNA. Two apparently...
A 24-hours service was organized to study changes in the hemostatic system surgical patients undergoing massive transfusion for excessive bleeding during operation or early postoperative period. Hemostasis tests gave normal results only 12(7%) of 172 patients, while remaining 160(93%) one more abnormal results. The platelet count most frequently abnormal, followed by prothrombin time and plasma fibrinogen. Well-defined disorders (such as DIC, heparinization liver disease) were ascertained 82...
Summary The bleeding patterns of severe von Willebrand's disease ( VWD ) adversely affect quality life, and may be life threatening. There is a presumed role for prophylaxis with VWF ‐containing concentrates, but data are scarce. Willebrand Disease Prophylaxis Network PN was formed to investigate the in clinically that not responsive other treatment(s).Using retrospective design, effect studied. Availability records document, or reliably assess, type frequency episodes prior to, after,...
Summary. von Willebrand disease (vWD) is a bleeding disorder caused by quantitative (type 1 and 3) or qualitative 2) defects of factor (vWF). The molecular basis type 2And 3 vWD are now known those being understood. Phenotypic diagnosis based on the measurements plasma platelet vWF, ability vWF to interact with receptors analysis multimeric structure vWF. Due heterogeneity variables that interfere levels, correct types subtypes may sometimes be difficult but very important for therapy. aim...
Summary. We have separated von Willebrand factor (vWF) multimers of different size into several fractions which were characterized by SDS‐agarose gel electrophoresis and measuring the ratio between ristocetin cofactor activity (Ricof) antigen (vWF:Ag) content. The pooled contained vWF with multimeric structures Ricof similar to those in plasma. pool was labelled 125 I used for inhibition binding studies individual calculate dissociation constants ( K d values expressed mol/I)...